This week’s research highlights include promising urine tests for invasive aspergillosis, new evidence about isavuconazole for chronic pulmonary aspergillosis (CPA), and research into antifungal resistance and the diagnosis of fungal lung infections.
These studies offer reasons for cautious optimism. Most are early-stage or observational investigations, however, and do not mean that established diagnostic or treatment recommendations have changed.
1. Could a urine test make invasive aspergillosis easier to diagnose?
Diagnosing invasive aspergillosis can be difficult, especially in people receiving treatment for blood cancers or whose immune systems are weakened. Doctors currently use a combination of scans, blood tests, respiratory samples and sometimes bronchoscopy.
Two new studies investigate whether substances released by Aspergillus fungi can be detected in urine.
Baburina and colleagues evaluated the urinary MycoMEIA Aspergillus assay, which detects fungal glycans. The study reported promising diagnostic accuracy in its evaluated population. However, further testing is needed to establish how reliably the assay performs in everyday clinical settings and in different patient groups.
A second prospective study by Patil and colleagues investigated a combination of urinary triacetylfusarinine C (uTafC), serum galactomannan and serum pentraxin-3 in patients with haematological malignancies.
Why this matters: A reliable urine-based test could make investigations easier for some seriously ill patients and potentially support earlier diagnosis. These tests are still being evaluated and cannot yet replace established diagnostic methods.
Research: Baburina et al., Clinical Infectious Diseases (2026); Patil et al., Clinical Microbiology and Infection (2026).
2. Isavuconazole may offer an alternative for people with chronic pulmonary aspergillosis
People with CPA often require many months or even years of antifungal treatment. Finding a medicine that controls infection without causing unacceptable side effects can be challenging.
Fama and colleagues examined the use of isavuconazole and voriconazole in a retrospective study of 40 patients with CPA.
The investigators reported frequent use of isavuconazole, often following difficulties with voriconazole tolerability, blood concentrations or interactions with other medicines. Therapeutic drug monitoring was used to help guide dosing, including reduced doses in selected patients.
Why this matters: Isavuconazole may provide another treatment option when other azole antifungals are unsuitable. However, this small observational study cannot prove that one drug is more effective than another. Decisions about treatment and dose adjustment require specialist supervision.
Research: Fama et al., Antimicrobial Agents and Chemotherapy (2026).
3. Are improvements in survival from invasive aspergillosis slowing down?
Antifungal treatments have improved considerably over recent decades, but invasive aspergillosis remains a serious infection, particularly in patients with haematological malignancies.
Szvalb and colleagues examined ten-year trends in deaths among patients with culture-confirmed invasive aspergillosis. Importantly, the researchers distinguished deaths directly attributable to aspergillosis from deaths where the infection contributed alongside other serious illnesses.
The study reported a decline in mortality directly attributable to aspergillosis, while highlighting the continuing complexity of outcomes in patients with blood cancers.
Why this matters: Better antifungal drugs are only one part of improving survival. Early diagnosis, immune recovery and treatment of underlying disease also matter. The findings should not be interpreted as showing that antifungal treatment has stopped improving.
Research: Szvalb et al., Clinical Infectious Diseases (2026).
4. Could combining antifungal drugs help overcome resistance?
Resistance to azole antifungal medicines is a growing concern, particularly in infections caused by Aspergillus fumigatus.
Wurster and colleagues investigated the combination of isavuconazole and micafungin against three azole-resistant A. fumigatus isolates.
The laboratory investigation found evidence of synergistic antifungal and immune-related activity, suggesting that the two drugs may work together in ways that deserve further investigation.
Why this matters: Combination treatment may eventually provide additional options for difficult resistant infections. However, laboratory synergy does not demonstrate improved survival or effectiveness in patients. Clinical evidence is still needed.
Research: Wurster et al., Journal of Infectious Diseases (2026).
5. Can advanced DNA sequencing distinguish fungal infection from colonisation?
Finding Aspergillus in the respiratory tract does not always mean it is causing disease. The fungus may sometimes be present without invading tissue or producing a clinically significant infection.
Zhao and colleagues studied metagenomic next-generation sequencing (mNGS) of bronchoalveolar lavage fluid in patients with suspected invasive pulmonary aspergillosis.
This technology can detect genetic material from a wide range of microorganisms. The researchers investigated how sequencing findings, other microorganisms and clinical information might help distinguish infection from colonisation.
Why this matters: More sensitive tests can identify fungi that conventional methods miss, but a positive result still needs careful interpretation. Symptoms, imaging, immune status and other laboratory findings remain essential.
Research: Zhao et al., Microbiology Spectrum (2026).
Other research this week
Immune cells in lung samples: Cho and colleagues studied bronchoalveolar lavage fluid from 63 patients with blood cancers and invasive pulmonary aspergillosis. Immune-cell patterns reflected blood-cell abnormalities and fungal burden but did not reliably predict short-term outcomes. Read the study.
How fungi regulate growth and virulence: Gao and colleagues investigated long non-coding RNAs involved in fungal biology. This is fundamental research rather than an immediately applicable diagnostic or treatment advance. Read the study.
Allergic bronchopulmonary mycosis caused by another fungus: A case report describes allergic bronchopulmonary mycosis associated with Talaromyces boninensis. It provides a reminder that allergic bronchopulmonary fungal disease is not always caused by Aspergillus. Read the case report.
What should patients take away from this week’s research?
- Diagnosis: Urine testing may eventually make diagnosing invasive aspergillosis easier, but established tests remain important.
- CPA treatment: Isavuconazole is an alternative worth discussing with a specialist when other antifungals cause problems.
- Drug resistance: Researchers continue to investigate combinations of antifungal medicines, although clinical benefits are not yet established.
- Interpreting results: Finding fungal material in a sample does not, by itself, prove that it is causing disease.
This research summary is provided for education and should not be used to change prescribed treatment without advice from a healthcare professional.
Did this page help you?
Tell us in one minute